Skip to content

MAKING BEST PRACTICE, EVERYDAY PRACTICE

FREE accredited digital CPD for health care professionals in South Africa

Accredited by the University of Pretoria

MAKING BEST PRACTICE, EVERYDAY PRACTICE

FREE accredited digital CPD for health care professionals in South Africa

Accredited by the University of Pretoria

Menu

Home
About
- About Us
- FAQs
- Sponsors
All clinical topics
SPECIAL INTEREST GROUPS
- Medical interns and registrars
Contact
ACCESS MY PROFILE

Menu

Home
About
- About Us
- FAQs
- Sponsors
All clinical topics
SPECIAL INTEREST GROUPS
- Medical interns and registrars
Contact
ACCESS MY PROFILE

[denovo_breadcrumbs]

Evidence-based approaches to T2D management – Insulin remains integral

Questionnaire

To access this module, please register or login:

Login or Register

Time limit: 0

Questionnaire Summary

0 of 10 Questions completed

Questions:

Information

You have already completed the questionnaire before. Hence you can not start it again.

Questionnaire is loading…

You must sign in or sign up to start the questionnaire.

You must first complete the following:

Results

Questionnaire complete. Results are being recorded.

Results

0 of 10 Questions answered correctly

Time has elapsed

You have reached 0 of 0 point(s), (0)

Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)

Categories

Not categorized 0%

Regrettably, you have failed to achieve the 70% pass mark required by the accrediting HPCSA.

Please read/watch the module carefully and try once more! (Only two tries are allowed)

PLEASE NOTE: you will no longer receive a fail confirmation email
Congratulations on successfully completing this FREE CPD module!

For HPCSA members only: No need to load your certificate on HPCSA, as deNovo Medica uploads these weekly. Please allow 5-10 working days for the CPD activity to reflect on your HPCSA profile.

For non-HPCSA members: The above button allows you to download and print your CPD certificate to submit to your council yourself.

PLEASE NOTE: you will no longer receive a pass confirmation email! Visit YOUR PROFILE to find all your CPD certificates and activities completed

Review
Answered
Correct
Incorrect

Question 1 of 10

1. Question

1. A Danish registry study of first-time GLP-1RA users has demonstrated a:

A. 20% treatment discontinuation within 12 months of initiation
Correct Incorrect Correct answer

B. 50% 18-month persistence to therapy
Correct Incorrect Correct answer

C. Both of the above
Correct Incorrect Correct answer

D. None of the above
Correct Incorrect Correct answer
Question 2 of 10

2. Question

2. Among challenges to achieving good glycaemic control with insulin therapy are complex and inflexible treatment regimens and fear of hypoglycaemia.

A. True
Correct Incorrect Correct answer

B. False
Correct Incorrect Correct answer
Question 3 of 10

3. Question

3. Benefits of combination therapy for the management of T2D include:

A. A simplified treatment regimen that improves adherence/persistence to therapy
Correct Incorrect Correct answer

B. Complementary mechanisms of action that target multifactorial pathophysiologies giving rise to hyperglycaemia
Correct Incorrect Correct answer

C. Both of the above
Correct Incorrect Correct answer

D. None of the above
Correct Incorrect Correct answer
Question 4 of 10

4. Question

4. The short-acting GLP-1RA, lixisenatide:

A. Has a low potential for hypoglycaemia
Correct Incorrect Correct answer

B. Is weight neutral
Correct Incorrect Correct answer

C. Has proven cardioprotective effects
Correct Incorrect Correct answer

D. All of the above
Correct Incorrect Correct answer

E. Only A and B
Correct Incorrect Correct answer
Question 5 of 10

5. Question

5. Clinical scenarios for which combination iGlarLixi therapy can be considered for the management of T2D include:

A. First-line therapy at the time of T2D diagnosis
Correct Incorrect Correct answer

B. Treatment intensification when uncontrolled on multiple OADs ± insulin
Correct Incorrect Correct answer

C. Treatment de-escalation when failing premix or basal-bolus insulin
Correct Incorrect Correct answer

D. All of the above
Correct Incorrect Correct answer

E. Only B and C
Correct Incorrect Correct answer
Question 6 of 10

6. Question

6. Compared with BIAsp 30 in uncontrolled T2D on basal insulin plus OADs, the SoliMix trial demonstrated superiority of iGlarLixi for:

A. HbA1c reduction
Correct Incorrect Correct answer

B. Body weight change
Correct Incorrect Correct answer

C. Change in total daily insulin dose
Correct Incorrect Correct answer

D. All of the above
Correct Incorrect Correct answer

E. Only A and C
Correct Incorrect Correct answer
Question 7 of 10

7. Question

7. A lower risk of any hypoglycaemic event was observed over 26 weeks in iGlarLixi treated compared with BIAsp 30-treated participants of the SoliMix trial.

A. True
Correct Incorrect Correct answer

B. False
Correct Incorrect Correct answer
Question 8 of 10

8. Question

8. The recommended iGlarLixi starting dose when switching from twice-daily basal insulin or insulin glargine 300 U/ml is:

A. 10 dose steps
Correct Incorrect Correct answer

B. 20 dose steps
Correct Incorrect Correct answer

C. 30 dose steps
Correct Incorrect Correct answer

D. 80% of the previous total daily insulin dose
Correct Incorrect Correct answer
Question 9 of 10

9. Question

9. Regarding the initiation of iGlarLixi therapy:

A. Administer once daily before the largest meal
Correct Incorrect Correct answer

B. Titrate and monitor based on FPG
Correct Incorrect Correct answer

C. Slow titration reduces adverse GI effects
Correct Incorrect Correct answer

D. All of the above
Correct Incorrect Correct answer

E. Only A and C
Correct Incorrect Correct answer
Question 10 of 10

10. Question

10. Compared with previous premixed insulin therapy, 24 weeks of iGlarLixi therapy in Soli-SWITCH study participants demonstrated a mean change in:

A. HbA1c of -1.2%
Correct Incorrect Correct answer

B. Total daily insulin dose +13 U
Correct Incorrect Correct answer

C. Body weight +2.3 kg
Correct Incorrect Correct answer

D. All of the above
Correct Incorrect Correct answer

All Rights Reserved 2026 © deNovo Medica (Pty) Ltd in South Africa. The content on this website is intended for healthcare related professionals unless stated otherwise.

Get involved

Become a sponsor Become a medical partner author/reviewer/society

Get involved

Become a sponsor Become a medical partner author/reviewer/society

Login

Accessing this module requires a login. Please enter your credentials below!

Username or Email Address

Password

Remember Me

Lost Your Password?